Real-World epilepsy study tracks Add-On drug effectiveness

NCT ID NCT05867160

Ongoing Knowledge-focused Sponsor: Aziende Chimiche Riunite Angelini Francesco S.p.A Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study follows 300 adults with focal epilepsy who are starting an additional anti-seizure medication (ASM) alongside their current treatment. Researchers will track changes in seizure frequency and quality of life over 12 months in everyday clinical settings. The goal is to see how well these add-on drugs work outside of strict trial conditions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: anti-seizure medication (ASM) as add-on therapy
What this could lead to: If successful, this study could help doctors understand which add-on seizure medicines work best in everyday settings for people with hard-to-control focal seizures.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all patients, and there is no new treatment being tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPILEPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

epilepsy visual epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPILEPSY

Contacts and locations

Locations

Fondazione IRCCS Istituto Neurologico "Carlo Besta" U.O. Epilettologia Clinica e Sperimentale - Centro di Medicina del Sonno

Milan, 20133, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.